Search: onr:"swepub:oai:DiVA.org:kth-121606" > Targeting HMG-CoA r...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06605naa a2200541 4500 | |
001 | oai:DiVA.org:kth-121606 | |
003 | SwePub | |
008 | 130503s2013 | |||||||||||000 ||eng| | |
009 | oai:lup.lub.lu.se:ee10e5c2-43af-428f-acc8-3c45054b1851 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-1216062 URI |
024 | 7 | a https://doi.org/10.1007/s10549-013-2473-62 DOI |
024 | 7 | a https://lup.lub.lu.se/record/36284202 URI |
040 | a (SwePub)kthd (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Bjarnadottir, Olöfu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)med-oba |
245 | 1 0 | a Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial |
264 | c 2013-03-08 | |
264 | 1 | b Springer Science and Business Media LLC,c 2013 |
338 | a print2 rdacarrier | |
500 | a QC 20130506 | |
520 | a Lipophilic statins purportedly exert anti-tumoral effects on breast cancer by decreasing proliferation and increasing apoptosis. HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway, is the target of statins. However, data on statin-induced effects on HMGCR activity in cancer are limited. Thus, this pre-operative study investigated statin-induced effects on tumor proliferation and HMGCR expression while analyzing HMGCR as a predictive marker for statin response in breast cancer treatment. The study was designed as a window-of-opportunity trial and included 50 patients with primary invasive breast cancer. High-dose atorvastatin (i.e., 80 mg/day) was prescribed to patients for 2 weeks before surgery. Pre- and post-statin paired tumor samples were analyzed for Ki67 and HMGCR immunohistochemical expression. Changes in the Ki67 expression and HMGCR activity following statin treatment were the primary and secondary endpoints, respectively. Up-regulation of HMGCR following atorvastatin treatment was observed in 68 % of the paired samples with evaluable HMGCR expression (P = 0.0005). The average relative decrease in Ki67 expression following atorvastatin treatment was 7.6 % (P = 0.39) in all paired samples, whereas the corresponding decrease in Ki67 expression in tumors expressing HMGCR in the pre-treatment sample was 24 % (P = 0.02). Furthermore, post-treatment Ki67 expression was inversely correlated to post-treatment HMGCR expression (rs = -0.42; P = 0.03). Findings from this study suggest that HMGCR is targeted by statins in breast cancer cells in vivo, and that statins may have an anti-proliferative effect in HMGCR-positive tumors. Future studies are needed to evaluate HMGCR as a predictive marker for the selection of breast cancer patients who may benefit from statin treatment. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a HMGCR | |
653 | a Ki67 | |
653 | a Statins | |
653 | a Breast cancer | |
653 | a Mevalonate pathway | |
700 | 1 | a Romero, Quinciu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)kkem-qro |
700 | 1 | a Bendahl, Pär-Olau Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-pbe |
700 | 1 | a Jirström, Karinu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)pat-kji |
700 | 1 | a Rydén, Lisau Lund University,Lunds universitet,Kirurgi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Surgery (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund4 aut0 (Swepub:lu)pat-lry |
700 | 1 | a Loman, Niklasu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-nlo |
700 | 1 | a Uhlén, Mathiasu KTH,Proteomik,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:kth)u1dulvmw |
700 | 1 | a Johannesson, Henriku Atlas Antibodies AB, AlbaNova University Center, Stockholm, Sweden4 aut0 (Swepub:kth)u1t5vc8g |
700 | 1 | a Rose, Carstenu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-cro |
700 | 1 | a Grabau, Dortheu Lund University,Lunds universitet,Kirurgi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Surgery (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund4 aut0 (Swepub:lu)med-dgu |
700 | 1 | a Borgquist, Signeu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)ront-sbo |
710 | 2 | a Bröstcancer-genetikb Sektion I4 org |
773 | 0 | t Breast Cancer Research and Treatmentd : Springer Science and Business Media LLCg 138:2, s. 499-508q 138:2<499-508x 0167-6806x 1573-7217 |
856 | 4 | u http://www.ncbi.nlm.nih.gov/pubmed/23471651?dopt=Abstracty FULLTEXT |
856 | 4 | u http://dx.doi.org/10.1007/s10549-013-2473-6y FULLTEXT |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-121606 |
856 | 4 8 | u https://doi.org/10.1007/s10549-013-2473-6 |
856 | 4 8 | u https://lup.lub.lu.se/record/3628420 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.